Will This Analyst Downgrade Hurt MedAssets (MDAS) Stock Today? (Update)

Update (9:47 a.m.): Updated with Thursday market open information.

NEW YORK (TheStreet) -- Bank of America/Merrill Lynch downgraded MedAssets  (MDAS) to "neutral" from "buy" and set a $24 price target. The firm cited valuation as the reason for the move.

The stock was down 2.65% to $22.79 at 9:47 a.m. on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MDAS Chart

MDAS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

New Lifetime High Reached By MedAssets (MDAS)

New Lifetime High Reached By MedAssets (MDAS)

MedAssets (MDAS) Reaches New Lifetime High Today

MedAssets (MDAS) Reaches New Lifetime High Today

MedAssets (MDAS) Stock Gains on Sale to Pamplona Capital Management

MedAssets (MDAS) Stock Gains on Sale to Pamplona Capital Management

Today MedAssets (MDAS) Hits New Lifetime High

Today MedAssets (MDAS) Hits New Lifetime High

Analysts' Actions -- Apple, Disney, Hershey and More

Analysts' Actions -- Apple, Disney, Hershey and More